A drug like Tysabri has a way of truly finding not just the weakness in a country's medical system but in pointing out the various ways the docs and infusion clinics handle the patients. Some of the stories written by these patients on the net really show what the varied level of care is with this medication.

And now Biogen and Elan are spending millions of dollars on new ways of detecting PML! To say that they were not looking for PML or similar conditions during the trials is simply not correct. Biogen was warned repeatedly by Dr. L. Steinman (one of Tysabr's founders) that these conditions were very probable and likely to occur. So what did they do?....push for approval after one year of Phase III trials which of course got them into a real mess!

You have to understand what Biogen and Elan are all about in the world of big pharma and IT'S NOT about the health of MS patients. It's about the bottom line and getting as much profit as they can.

Tysabri is an immensely expensive drug to use and the follow up costs with patient monitoring and MRI's is making it beyond expensive. The efficacy has been similar to other MS drugs....some do very well on it, others more or less remain the same and some become very sick and have to stop it altogether. I guess time will tell if it was worth it.

Harry